References:
1. Fischer M, Schmutzhard E. Posterior reversible encephalopathy
syndrome. J Neurol. 2017;264(8):1608-1616. doi:10.1007/s00415-016-8377-8
2. Huenges K, Kolat P, Panholzer B, Haneya A. CSA-Induced PRES after
Heart Transplantation-Report of Two Cases and Review. Thorac Cardiovasc
Surg Rep. 2021;10(1):e59-e60. doi:10.1055/s-0041-1732344
3. Ishikura K, Ikeda M, Hamasaki Y, et al. Nephrotic state as a risk
factor for developing posterior reversible encephalopathy syndrome in
paediatric patients with nephrotic syndrome. Nephrol Dial Transplant Off
Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2008;23(8):2531-2536.
doi:10.1093/ndt/gfn013
4. de Oliveira RA, Fechine LM, Neto FC, Nicodemus JM, Silva GB, Silva
LSV. Posterior reversible encephalopathy syndrome (PRES) induced by
cyclosporine use in a patient with collapsing focal glomeruloesclerosis.
Int Urol Nephrol. 2008;40(4):1095-1098. doi:10.1007/s11255-008-9431-y
5. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior
leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500.
doi:10.1056/NEJM199602223340803
6. Roy S, Gandhi AK, Jana M, Julka PK. Recurrent posterior reversible
encephalopathy syndrome after chemotherapy in hematologic
malignancy-posterior reversible encephalopathy syndrome can strike
twice!!! J Cancer Res Ther. 2014;10(2):393-396.
doi:10.4103/0973-1482.136668
7. Lee VH, Wijdicks EFM, Manno EM, Rabinstein AA. Clinical spectrum of
reversible posterior leukoencephalopathy syndrome. Arch Neurol.
2008;65(2):205-210. doi:10.1001/archneurol.2007.46
8. Tullus K, Webb H, Bagga A. Management of steroid-resistant nephrotic
syndrome in children and adolescents. Lancet Child Adolesc Health.
2018;2(12):880-890. doi:10.1016/S2352-4642(18)30283-9
9. Zhang Y, Zhou J, Chen Y. Posterior reversible encephalopathy syndrome
in a child with steroid-resistant nephrotic syndrome: a case report and
review of literature. Int J Clin Exp Pathol. 2014;7(7):4433-4437.
10. Yamada A, Atsumi M, Tashiro A, Hiraiwa T, Ueda N. Recurrent
posterior reversible encephalopathy syndrome in nephrotic syndrome: case
report and review of the literature. Clin Nephrol. 2012;78(5):406-411.
doi:10.5414/cn106976
11. Shuto H, Kataoka Y, Fujisaki K, et al. Inhibition of GABA system
involved in cyclosporine-induced convulsions. Life Sci.
1999;65(9):879-887. doi:10.1016/s0024-3205(99)00318-5
12. Zhou J, Zheng H, Zhong X, et al. Reversible posterior encephalopathy
syndrome in children with nephrotic syndrome. Nephrol Carlton Vic.
2015;20(11):849-854. doi:10.1111/nep.12518
13. Lallana S, Chen A, Requena M, et al. Posterior reversible
encephalopathy syndrome (PRES) associated with COVID-19. J Clin Neurosci
Off J Neurosurg Soc Australas. 2021;88:108-112.
doi:10.1016/j.jocn.2021.03.028
14. Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and
complications associated with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J
Neurol. 2021;268(9):3059-3071. doi:10.1007/s00415-021-10406-y
15. Kishfy L, Casasola M, Banankhah P, et al. Posterior reversible
encephalopathy syndrome (PRES) as a neurological association in severe
Covid-19. J Neurol Sci. 2020;414:116943. doi:10.1016/j.jns.2020.116943
16. Gewirtz AN, Gao V, Parauda SC, Robbins MS. Posterior Reversible
Encephalopathy Syndrome. Curr Pain Headache Rep. 2021;25(3):19.
doi:10.1007/s11916-020-00932-1
17. Heiss S, Krampla W, Klauser-Braun R. A patient recently transplanted
with a living donor kidney develops severe neurological symptoms.
Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc.
2006;21(7):2017-2019. doi:10.1093/ndt/gfl239
18. Poule rsssssslsen NN, von Brunn A, Hornum M, Blomberg Jensen M.
Cyclosporine and COVID-19: Risk or favorable? Am J Transplant Off J Am
Soc Transplant Am Soc Transpl Surg. 2020;20(11):2975-2982.
doi:10.1111/ajt.16250
19. McKinney AM, Short J, Truwit CL, et al. Posterior reversible
encephalopathy syndrome: incidence of atypical regions of involvement
and imaging findings. AJR Am J Roentgenol. 2007;189(4):904-912.
doi:10.2214/AJR.07.2024